Cellular and Molecular Neurobiology

, Volume 26, Issue 4–6, pp 363–382 | Cite as

Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis

Article

 

1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals.

2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia.

3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission.

4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications.

5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.

KEY WORDS:

schizophrenia dopamine glutamate d-serine glycine negative symptoms d-amino acid oxidase 

Notes

ACKNOWLEDGMENTS

Some of the research described in this review was supported by a National Institute of Mental Health Conte Center on the Neurobiology of Schizophrenia (MH P50-60450) and MH RO1-572901 and a Lieber Senior Investigator Award from the National Alliance for Research on Schizophrenia and Affective Disorder (NARSAD) to JTC.

REFERENCES

  1. Addington, A. M., Gornick, M., Sporn, A. L., Gogtay, N., Greenstein, D., Lenane, M., Gochman, P., Baker, N., Balkissoon, R., Vakkalanka, R. K., Weinberger, D. R., Straub, R. E., and Rapoport, J. L. (2004). Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biol. Psychiatry 55:976–980.PubMedGoogle Scholar
  2. Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T., Egan, M., Pickar, D., and Breier, A. (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 156:1646–1649.PubMedGoogle Scholar
  3. Andersen, J. M., Lindberg, V., and Myhrer, T. (2002). Effects of scopolamine and D-cycloserine on non-spatial reference memory in rats. Behav. Brain Res. 129:211–216.PubMedGoogle Scholar
  4. Araque, A., Parpura, V., Sanzgiri, R. P., and Haydon, P. G. (1999). Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22:208–215.PubMedGoogle Scholar
  5. Auer, D. P., Wilke, M., Grabner, A., Heidenreich, J. O., Bronisch, T., and Wetter, T. C. (2001). Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr. Res. 52:87–99.PubMedGoogle Scholar
  6. Benes, F. M., and Berretta, S. (2001). GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1–27.PubMedGoogle Scholar
  7. Benes, F. M., Vincent, S. L., Marie, A., and Khan, Y. (1996). Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75:1021–1031.PubMedGoogle Scholar
  8. Benes, F. M., McSparren, J., Bird, E. D., SanGiovanni, J. P., and Vincent, S. L. (1991). Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry 48:996–1001.PubMedGoogle Scholar
  9. Berger, A. J., Dieudonne, S., and Ascher, P. (1998). Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol. 80(6):3336–3340.Google Scholar
  10. Berger, U. V., Luthi-Carter, R., Passani, L. A., Elkabes, S., Black, I., Konradi, C., and Coyle, J. T. (1999). Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J. Comp. Neurol. 415:52–64.PubMedGoogle Scholar
  11. Bergeron, R., Coyle, J. T., Tsai, G., and Greene, R. W. (2005). NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 30:7–16.PubMedGoogle Scholar
  12. Bergeron, R., Meyer, T. M., Coyle, J. T., and Greene, R. W. (1998). Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Nat.l Acad. Sci. U.S.A. 95:15730–15734.Google Scholar
  13. Berman, K. F., Zec, R. F., and Weinberger, D. R. (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry. 43(2):126–135.Google Scholar
  14. Berretta, S., Lange, N., Bhattacharyya, S., Sebro, R., Garces, J., and Benes, F. M. (2004). Long-term effects of amygdala GABA receptor blockade on specific subpopulations of hippocampal interneurons. Hippocampus 14:876–894.PubMedGoogle Scholar
  15. Bischofberger, J., and Schild, D. (1996). Glutamate and N-acetylaspartylglutamate block HVA calcium currents in frog olfactory bulb interneurons via an mGluR2/3-like receptor. J. Neurophysiol. 76:2089–2092.PubMedGoogle Scholar
  16. Blake, D. J., Nawrotzki, R., Loh, N. Y., Gorecki, D. C., and Davies, K. E. (1998). Beta-dystrobrevin, a member of the dystrophin-related protein family. Proc. Natl. Acad. Sci. U. S. A. 95(1):241–246.PubMedGoogle Scholar
  17. Braff, D. L., Geyer, M. A., and Swerdlow, N. R. (2001). Human studies of prepulse inhibition of startle: Normal subjects, patient groups,and pharmacological studies. Psychopharmacology (Berl). 156(2–3):234–258.Google Scholar
  18. Buchanan, R. W., Davis, M., Goff, D., Green, M. F., Keefe, R. S., Leon, A. C., Nuechterlein, K. H., Laughren, T., Levin, R., Stover, E., Fenton, W., and Marder, S. R. (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 31(1):5–19.Google Scholar
  19. Burdick, K. E., Lencz, T., Funke, B., Finn, C. T., Szeszko, P. R., Kane, J. M., Kucherlapati, R., and Malhotra, A. K. (in press). Genetic Variation in DTNBP1 Influences General Cognitive Ability. Hum. Mol. Genet. Google Scholar
  20. Butler, P. D., Zemon, V., Schechter, I., Saperstein, A. M., Hoptman, M. J., Lim, K. O., Revheim, N., Silipo, G., and Javitt, D. C. (2005). Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch. Gen. Psychiatry 62:495–504.PubMedGoogle Scholar
  21. Cannon, T. D., Hennah, W., van Erp, T. G., Thompson, P. M., Lonnqvist, J., Huttunen, M., Gasperoni, T., Tuulio-Henriksson, A., Pirkola, T., Toga, A. W., Kaprio, J., Mazziotta, J., and Peltonen, L. (2005). Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch. Gen. Psychiatry 62:1205–1213.PubMedGoogle Scholar
  22. Chen, L., Muhlhauser, M., and Yang, C. R. (2003). Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. 89:691–703.PubMedGoogle Scholar
  23. Chen, Y. S., Akula, N., Detera-Wadleigh, S. D., Schulze, T. G., Thomas, J., Potash, J. B., DePaulo, J. R., Mclnnis, M. G., Cox, N. J., and McMahon, L. F. J. (2004). Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33. Mol. Psychiatry. 9(1):87–92.PubMedGoogle Scholar
  24. Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., et al. (2002). Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S .A. 99:13675–13680.PubMedGoogle Scholar
  25. Coyle, J. T. (1998). Alzheimer's disease, molecular biology and the future of rational neuropsychotropic drug development. Int. Acad. Biomed. Drug. Res., Karger, Basel 13:76–83.Google Scholar
  26. Coyle, J. T., and Schwarcz, R. (2000). Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry 57:90–93.PubMedGoogle Scholar
  27. Coyle, J. T., and Schwarcz, R., (1976). Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263:244–246.PubMedGoogle Scholar
  28. Coyle, J. T., and Tsai, G. (2004). The NMDA receptor glycine modulatory site: A therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174:32–38.Google Scholar
  29. Coyle, J. T., Tsai, G., and Goff, D. C. (2002). Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 1:183–189.PubMedGoogle Scholar
  30. Davis, J. M., Chen, N., and Glick, I. D. (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60:553–564.PubMedGoogle Scholar
  31. Deicken, R. F., Pegues, M., and Amend, D. (1999). Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophr. Res. 37:217–223.PubMedGoogle Scholar
  32. DeLisi, L. E., Sakuma, M., Maurizio, A. M., Relja, M., and Hoff, A. L. (2004). Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatry Res. 130:57–70.PubMedGoogle Scholar
  33. Drake, R. E., Xie, H., McHugo, G. J., and Green, Al. (2000). The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 26(2):441–449.Google Scholar
  34. Egan, M. F., Straub, R. E., Goldberg, T. E., Yakub, I., Callicott, J. H., Hariri, A. R., Mattay, V. S., Bertolino, A., Hyde, T. M., Shannon-Weickert, C., Akil, M., Crook, J., Vakkalanka, R. K., Balkissoon, R., Gibbs, R. A., Kleinman, J. E., and Weinberger, D. R. (2004). Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad . Sci. U. S. A. 101:12604–12609.PubMedGoogle Scholar
  35. Erhardt, S., Schwieler, L., Emanuelsson, C., and Geyer, M. (2004). Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry 56:255–260.PubMedGoogle Scholar
  36. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L. H., and Engberg, G. (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313:96–98.PubMedGoogle Scholar
  37. Evans, J. D., Bond, G. R., Meyer, P. S., Kim, H. W., Lysaker, P. H., Gibson, P. J., and Tunis, S. (2004). Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. Schizophr. Res. 70:331–342.PubMedGoogle Scholar
  38. Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., and Goff, D. C. (2000). Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry 157:826–828.PubMedGoogle Scholar
  39. Falls, D. L. (2003). Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284:14–30.PubMedGoogle Scholar
  40. Gisabella, B., Bolshakov, V. Y., and Benes, F. M. (2005). Regulation of synaptic plasticity in a schizophrenia model. Proc. Natl. Acad .Sci. U. S. A. 102:13301–13306.PubMedGoogle Scholar
  41. Goff, D. C., Henderson, D. C., Evins, A. E., and Amico, E. (1999). A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry 45(4):512–524.PubMedGoogle Scholar
  42. Goff, D. C., Herz, L., Posever, T., Shih, V., Tsai, G., Henderson, D. C., Freudenreich, O., Evins, A. E., Yovel, I., Zhang, H., and Schoenfeld, D. (2005). A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179:144–150.Google Scholar
  43. Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., et al. (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56:21–27.PubMedGoogle Scholar
  44. Goff, D. C., Tsai, G., Manoach, D. S., Flood, J., Darby, D. G., and Coyle, J. T. (1996). D-cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry 153:1628–1630.PubMedGoogle Scholar
  45. Goff, D. C., Tsai, G., Manoach, D. S., and Coyle, J. T. (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152:1213–1215.PubMedGoogle Scholar
  46. Gogtay, N., Sporn, A., Clasen, L. S., Nugent, T. F., IIIrd, Greenstein, D., Nicolson, R., et al. (2004). Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses. Arch. Gen. Psychiatry 61:17–22.PubMedGoogle Scholar
  47. Goldberg, T. E., Egan, M. F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, B. S., Goldman, D., and Weinberger, D. R. (2003). Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60:889–896.PubMedGoogle Scholar
  48. Gomeza, J., Hulsmann, S., Ohno, K., Eulenburg, V., Szoke, K., Richter, D., and Betz, H. (2003). Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron 40:785–796.PubMedGoogle Scholar
  49. Gornick, M. C., Addington, A. M., Sporn, A., Gogtay, N., Greenstein, D., Lenane, M., Gochman, P., Ordonez, A., Balkissoon, R., Vakkalanka, R., Weinberger, D. R., Rapoport, J. L., and Straub, R. E. (in press). Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the premorbid adjustment scale (PAS). J. Autism Dev. Disord. Google Scholar
  50. Grunze, H. C., Rainnie, D. G., Hasselmo, M. E., Barkai, E., Hearn, E. F., McCarley, R. W., et al. (1996). NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16:2034–2043.Google Scholar
  51. Gu, Z., Jiang, Q., Fu, A. K., Ip, N. Y., and Yan, Z. (2005). Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J. Neurosci. 25:4974–4984.PubMedGoogle Scholar
  52. Guastella, J., Brecha, N., Weigmann, C., Lester, H. A., and Davidson, N. (1992). Cloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc. Natl. Acad. Sci. U. S. A. 89:7189–7193.PubMedGoogle Scholar
  53. Hakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., et al. (2001). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98:4746–4751.PubMedGoogle Scholar
  54. Hanada, S., Mita, T., Nishino, N., and Tanaka, C. (1987). [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci. 40:259–266.PubMedGoogle Scholar
  55. Hashimoto, A. (2002). Effect of the intracerebroventricular and systemic administration of L-serine on the concentrations of D- and L-serine in several brain areas and periphery of rat. Brain Res. 955:214–220.PubMedGoogle Scholar
  56. Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindstrom, L. H., and Iyo, M. (2005). Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29:767–769.PubMedGoogle Scholar
  57. Harrison, P. J., and Owen, M. J. (2003). Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 361:417–419. Review.PubMedGoogle Scholar
  58. Harrison, P. J., and Weinberger, D. R. (2005). Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol. Psychiatry 10:40–68.PubMedGoogle Scholar
  59. Hashimoto, A., and Chiba, S. (2004). Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat. Eur. J. Pharmacol. 495:153–158.PubMedGoogle Scholar
  60. Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., et al. (2003). Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60:572–576.PubMedGoogle Scholar
  61. Hattori, E., Liu, C., Badner, J. A., Bonner, T. I., Christian, S. L., Maheshwari, M., et al. (2003). Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am. J .Hum. Genet. 72:1131–1140.PubMedGoogle Scholar
  62. Heckers, S. (2001). Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 11(5):520–528.PubMedGoogle Scholar
  63. Heckers, S., Rauch, S. L., Goff, D., Savage, C. R., Schacter, D. L., Fischman, A. J., and Alpert, N. M. (1998). Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat. Neurosci. 1:318–323.PubMedGoogle Scholar
  64. Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., and Javitt, D. C. (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159:480–482.PubMedGoogle Scholar
  65. Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., and Lichtenstein, M. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56:29–36.PubMedGoogle Scholar
  66. Hill, J. J., Hashimoto, T., and Lewis, D. A. (in press). Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry.Google Scholar
  67. Holzman, P. S., Kringlen, E., Matthysse, S., Flanagan, S. D., Lipton, R. B., Cramer, G., Levin, S., Lange, K. and Levy, D. L. (1988). A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch. Gen. Psychiatry 45:641–647.PubMedGoogle Scholar
  68. Hong, S. J., Li, H., Becker, K. G., Dawson, V. L., and Dawson, T. M. (2004). Identification and analysis of plasticity-induced late-response genes. Proc. Natl. Acad. Sci. U.S.A. 100:2145–2150.Google Scholar
  69. Huffacker, S. J., Ryan, M., Sudhakaran, P., Webster, M., Groeder, T. M., and Bahn, S. (2003). Large scale gene chip analysis of post-mortem brains from schizophrenia and bipolar affect in disorder patients. Society for Neuroscience Abstracts Program No. 312.16.Google Scholar
  70. Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., Pappas, G. D., Tueting, P., Sharma, R. P., and Costa, E. (1998). A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 95:15718–15723.PubMedGoogle Scholar
  71. Itil, T., Keskiner, A., Kiremitci, N., and Holden, J. M. (1967). Effect of phencyclidine in chronic schizophrenics. Can. Psychiatr. Assoc. J. 12:209–212.PubMedGoogle Scholar
  72. Javitt, D. C., Duncan, L., Balla, A., and Sershen, H. (2005). Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action. Mol. Psychiatry 10:275–287.PubMedGoogle Scholar
  73. Javitt, D. C., Silipo, G., Cienfuegos, A., Shelley, A. M., Bark, N., Park, M., et al. (2001). Adjunctive Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 4:385–391.PubMedCrossRefGoogle Scholar
  74. Javitt, D. C., Balla, A., Sershen, H., and Lajtha, A. (1999). Reversal of the behavioral and neurochemical effects of phencylidine by glycine and glycine transport inhibitors. Biol. Psychiatry 45:668–679.PubMedGoogle Scholar
  75. Javitt, D. C., Steinschneider, M., Schroeder, C. E., and Arezzo, J. C. (1996). Role, of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: Implications for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 93:11962–11967.PubMedGoogle Scholar
  76. Javitt, D. C., Steinschneider, M., Schroeder, C. E., Vaughan, H. G., Jr., and Arezzo, J. C. (1994). Detection of stimulus deviance within primate primary auditory cortex: Intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res. 667:192–200.PubMedGoogle Scholar
  77. Javitt, D. C., and Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. Am. J.Psychiatry. 148:1301–308.PubMedGoogle Scholar
  78. Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., and Laruelle, M. (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 48:627–640.PubMedGoogle Scholar
  79. Kinney, G. G., Sur, C., Burno, M., Mallorga, P. J., Williams, J. B., Figueroa, D. J., Wittmann, M., Lemaire, W., and Conn, P. J. (2003). The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. 23:7586–7591.PubMedGoogle Scholar
  80. Kirov, G., O’Donovan, M. C., and Owen, M. J. (2005). Finding schizophrenia genes. J. Clin. Invest. 115:1440–1448.Google Scholar
  81. Kirkpatrick, B., Buchanan, R. W., Ross, D. E., and Carpenter, W. T., Jr. (2001). A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 58(2):165–171.PubMedGoogle Scholar
  82. Korostishevsky, M., Kremer, I., Kaganovich, M., Cholostoy A., Murad, I., Muhaheed, M., Bannoura, I., Rietschel, M., Dobrusin, M., Bening-Abu-Shach, U., Belmaker, R. H., Maier, W., Ebstein, R. P., and Navon, R. (2006). Transmission disequilibrium and haplotype analyses of the G72/G30 locus: Suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141: 91–95. Google Scholar
  83. Korostishevsky, M., Kaganovich, M., Cholostoy, A., Ashkenazi, M., Ratner, Y., Dahary, D., et al. (2004). Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol. Psychiatry 56:169–176.PubMedGoogle Scholar
  84. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51:199–214.PubMedGoogle Scholar
  85. Kuperberg, G. R., Broome, M. R., McGuire, P. K., David, A. S., Eddy, M., Ozawa, F., Goff, D., West, W. C., Williams, S. C., van der Kouwe, A. J., Salat, D. H., Dale, A. M., and Fischl, B. (2003). Regionally localized thinning of the cerebral cortex in schizophrenia. Arch, Gen. Psychiatry Sep 60(9):878–888.Google Scholar
  86. Land, C., and Riccio, D. C. (1999). d-Cycloserine: Effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem. 72:158–168.PubMedGoogle Scholar
  87. Llado, J., Caldero, J., Ribera, J., Tarabal, O., Oppenheim, R. W., and Esquerda, J. E. (1999). Opposing effects of excitatory amino acids on chick embryo spinal cord motoneurons: excitotoxic degeneration or prevention of programmed cell death. J. Neurosci. 19:10803–10812.PubMedGoogle Scholar
  88. Lahti, A. C., Weiler, M. A., Tamara Michaelidis, B. A., Parwani, A., and Tamminga, C. A. (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455–467.PubMedGoogle Scholar
  89. Lane, H. Y., Chang, Y. C., Liu, Y. C., Chiu, C. C., and Tsai, G. E. (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry. 62:1196–204.PubMedGoogle Scholar
  90. Leiderman, E., Zylberman, I., Zukin, S. R., Cooper, T. B., and Javitt, D. C. (1996). Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: An open-label trial. Biol. Psychiatry 39:213–215.PubMedGoogle Scholar
  91. Lewis, D. A., Volk, D. W., and Hashimoto, T. (2004). Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174:143–150.Google Scholar
  92. Li, Q., Clark, S., Lewis, D. V., and Wilson, W. A. (2002). NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: A potential mechanism of neurotoxicity. J. Neurosci. 22:3070–3080.PubMedGoogle Scholar
  93. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., and Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl. J. Med. 353:1209–1223.PubMedGoogle Scholar
  94. Lisman, J. E., Grace, A. A. (2005). The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46:703–713.PubMedGoogle Scholar
  95. Lisman, J. E., and Otmakhova, N. A. (2001). Storage, recall, and novelty detection of sequences by the hippocampus: Elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine. Hippocampus 11:551–568.PubMedGoogle Scholar
  96. Liu, L., Wong, T. P., Pozza, M. F., Lingenhoehl, K., Wang, Y., Sheng, M., Auberson, Y. P., and Wang, Y. T. (2004). Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304:1021–1024.PubMedGoogle Scholar
  97. Liu, H., Heath, S. C., Sobin, C., Roos, J. L., Galke, B. L., Blundell, M. L., Lenane, M., Robertson, B., Wijsman, E. M., Rapoport, J. L., Gogos, J. A., and Karayiorgou, M. (2002). Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 99:3717–3722.PubMedGoogle Scholar
  98. Luby, E. D., Cohen, B. D., Rosenbaum, G., Gottlieb, J. S., and Kelley, R. (1959). Study of a new schizophrenomimetic drug; sernyl. AMA Arch. Neurol. Psychiatry 81:363–369.PubMedGoogle Scholar
  99. Lynch, D. R., and Guttmann, R. P. (2001). NMDA receptor pharmacology: Perspectives from molecular biology. Curr. Drug Targets. 2:215–231.PubMedGoogle Scholar
  100. Malenka, R. C. (2003). The long-term potential of LTP. Nat. Rev. Neurosci. 4:923–926PubMedGoogle Scholar
  101. Matsui, T., Sekiguchi, M., Hashimoto, A., Tomita, U., Nishikawa, T., and Wada, K. (1995). Functional comparison of D-serine and glycine in rodents: The effect on cloned NMDA receptors and the extracellular concentration. J. Neurochem. 65:454–458.PubMedCrossRefGoogle Scholar
  102. Meltzer, H. Y., Alphs, L., Green, A. I., Altamura, A. C., Anand, R., Bertoldi, A., et al. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60:82–91.PubMedGoogle Scholar
  103. Meltzer, H., and McGurk, S. (1999). The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25:233–255.PubMedGoogle Scholar
  104. Meltzer, H. Y. (1997). Treatment-resistant schizophrenia–the role of clozapine. Curr. Med. Res. Opin. 14:1–20.PubMedGoogle Scholar
  105. Meyer-Lindenberg, A., Poline, J. B., Kohn, P. D., Holt, J. L., Egan, M. F., Weinberger, D. R., and Berman, K. F. (2001). Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am. J. Psychiatry 158:1809–1817.PubMedGoogle Scholar
  106. Miller, C. L., Llenos, I. C., Dulay, J. R., Barillo, M. M., Yolken, R. H., and Weis, S. (2004). Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 15:618–629.PubMedGoogle Scholar
  107. Mittelman, S. A., Shihabuddin, L., Brickman, A. M., Hazlett, E. A., and Buchsbaum, M. S. (2003). MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. Am. J. Psychiatry 160:2154–2168.Google Scholar
  108. Newcomer, J. W., Farber, N. B., Jevtovic-Todorovic, V., Selke, G., Melson, A. K., Hershey, T., Craft, S., and Olney, J. W. (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118.PubMedGoogle Scholar
  109. Nilsson, L. K., Linderholm, K. R., Engberg, G., Paulson, L., Blennow, K., Lindstrom, L. H., Nordin, C., Karanti, A., Persson, P., and Erhardt, S. (2005). Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 80:315–322.PubMedGoogle Scholar
  110. Ninan, I., Jardemark, K. E., and Wang, R. Y. (2003). Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pryramidal cells of the rat medial prefrontal cortex. Synapse 48:66–79.PubMedGoogle Scholar
  111. Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N., Ozaki, N., Taguchi, T., Tatsumi, M., Kamijima, K., Straub, R. E., Weinberger, D. R., Kunugi, H., and Hashimoto, R. (2004). Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 13:2699–2708.PubMedGoogle Scholar
  112. Oldendorf, W. H. (1971). Uptake of radiolabeled essential amino acids by brain following arterial injection. Proc. Soc. Exp. Biol. Med. 136:385–386.PubMedGoogle Scholar
  113. Passani, L. A., Vonsattel, J. P., and Coyle, J. T. (1997). Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res. 772:9–22.PubMedGoogle Scholar
  114. Paulson, L., Martin, P., Persson, A., Nilsson, C. L., Ljung, E., Westman-Brinkmalm, A., Eriksson, P. S., Blennow, K., and Davidsson, P. (2003). Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 71:526–533.PubMedGoogle Scholar
  115. Petryshen, T. L., Middleton, F. A., Kirby, A., Aldinger, K. A., Purcell, S., Tahl, A. R., Morley, C. P., McGann, L., Gentile, K. L., Rockwell, G. N., Medeiros, H. M., Carvalho, C., Macedo, A., Dourado, A., Valente, J., Ferreira, C. P., Patterson, N. J., Azevedo, M. H., Daly, M. J., Pato, C. N., Pato, M. T., and Sklar, P. (2005). Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol. Psychiatry 10:366–374.PubMedGoogle Scholar
  116. Quartermain, D., Mower, J., Raffertyc, M. F., Hertingc, R. L., and Lanthornc, T. H. (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur. J. Pharmacol. 257:7–12.PubMedGoogle Scholar
  117. Radant, A. D., Bowdle, T. A., Cowley, D. S., Kharasch, E. D., and Roy-Byrne, P. P. (1998). Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19:434–444.PubMedGoogle Scholar
  118. Reich, D. L., and Silvay, G. (1989). Ketamine: an update on the first twenty-five years of clinical experience. Can. J. Anaesth. 36:186–197.PubMedCrossRefGoogle Scholar
  119. Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., and Davis, M. (2004). Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 61:1136–1144.PubMedGoogle Scholar
  120. Schell, M. J. (2004). The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 359:943–964.PubMedGoogle Scholar
  121. Schluter, K., Figiel, M., Rozyczka, J., and Engele, J. (2002). CNS region-specific regulation of glial glutamate transporter expression. Eur. J. Neurosci. 16:836–842.PubMedGoogle Scholar
  122. Schousboe, A. (2003). Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem Res. 28(2):347–352.Google Scholar
  123. Schumacher, J., Jamra, R. A., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A. C., et al. (2004). Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol. Psychiatry 9:203–207.PubMedGoogle Scholar
  124. Schumacher, J., Jamra, R. A., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A. C., Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 319:1281–1286.Google Scholar
  125. Schwarcz, R., Rassoulpour, A., Wu, H. Q., Medoff, D., Tamminga, C. A., and Roberts, R. C. (2001). Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50:521–530.PubMedGoogle Scholar
  126. Seeman, P. (2002). Atypical antipsychotics: Mechanism of action. Can. J. Psychiatry 47:27–38.PubMedGoogle Scholar
  127. Selemon, L. D., Mrzljak, J., Kleinman, J. E., Herman, M. M., and Goldman-Rakic, P. S. (2003). Regional specificity in the neuropathologic substrates of schizophrenia: A morphometric analysis of Broca's area 44 and area 9. Arch. Gen. Psychiatry 60:69–77.PubMedCrossRefGoogle Scholar
  128. Sigmundsson, T., Maier, M., Toone, B. K., Williams, S. C., Simmons, A., Greenwood, K., et al. (2003). Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 64:63–71.PubMedGoogle Scholar
  129. Simmons, M. L., Frondoza, C. G., and Coyle, J. T. (1991). Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45:37–45.PubMedGoogle Scholar
  130. Snyder, S. H. (1981). Dopamine receptors, neuroleptics, and schizophrenia. Am. J. Psychiatry 138:460–464.PubMedGoogle Scholar
  131. Stevens, E. R., Esguerra, M., Kim, P. M., Newman, E. A., Snyder, S. H., Zahs, K. R., and Miller, R. F. (2003). D-serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors. Proc. Natl. Acad. Sci. U. S. A. 100:6789–6794.PubMedGoogle Scholar
  132. Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, R. J., Hahn, C. G., Siegel, S. J., Trojanowski, J. Q., Gur, R. E., Blake, D. J., and Arnold, S. E. (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest. 113:1353–1363.PubMedGoogle Scholar
  133. Thoma, R. J., Hanlon, F. M., Moses, S. N., Ricker, D., Huang, M., Edgar, C., Irwin, J., Torres, F., Weisend, M. P., Adler, L. E., Miller, G. A., and Canive, J. M. (2005). M50 sensory gating predicts negative symptoms in schizophrenia. Schizophr. Res. 73:311–318.PubMedGoogle Scholar
  134. Tsai, G., Lane, H. Y., Yang, P., Chong, M. Y., and Lange, N. (2004). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55:452–456.PubMedGoogle Scholar
  135. Tsai, G., Ralph-Williams, R. J., Martina, M., Bergeron, R., Berger-Sweeney, J., Dunham, K. S., Jiang, Z., Caine, S. B., and Coyle, J. T. (2004). Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc. Natl. Acad. Sci. U. S. A. 101:8485–8490.PubMedGoogle Scholar
  136. Tsai, G. E., Yang, P., Chung, L. C., Tsai, I. C., Tsai, C. W., and Coyle, J. T. (1999). D-serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry 156:1822–1825.PubMedGoogle Scholar
  137. Tsai, G., Yang, P., Chung, L. C., Lange, N., and Coyle, J. T. (1998). D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44:1081–1089.PubMedGoogle Scholar
  138. Tsai, G., Passani, L. A., Slusher, B. S., Carter, R., Baer, L., Kleinman, J. E., et al. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52:829–836.PubMedGoogle Scholar
  139. Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., and Javitt, D. C. (2000). Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry. 57:1139–1147.PubMedGoogle Scholar
  140. van der Stelt, O., Lieberman, J. A., and Belger, A. (2005). Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophr. Res. 77:309–320.PubMedGoogle Scholar
  141. Volk, D. W., Pierri, J. N., Fritschy, J. M., Auh, S., Sampson, A. R., and Lewis, D. A. (2002). Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 12:1063–1070.PubMedGoogle Scholar
  142. Volk, D., Austin, M., Pierri, J., Sampson, A., and Lewis, D. (2001). GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: Decreased expression in a subset of neurons. Am. J. Psychiatry. 158:256–265.PubMedGoogle Scholar
  143. Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 319:1281–1286.PubMedGoogle Scholar
  144. Watson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L., and Lanthorn, T. H. (1990). D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 510:158–160.PubMedGoogle Scholar
  145. Weickert, C. S., Straub, R. E., McClintock, B. W., Matsumoto, M., Hashimoto, R., Hyde, T. M., Herman, M. M., Weinberger, D. R., and Kleinman, J. E. (2004). Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry 61:544–555.PubMedGoogle Scholar
  146. Williams, N. M., Preece, A., Spurlock, G., Norton, N., Williams, H. J., McCreadie, R. G., Buckland, P., Sharkey, V., Chowdari, K. V., Zammit, S., Nimgaonkar, V., Kirov, G., Owen, M. J., and O’Donovan, M. C. (2004). Support for RGS4 as a susceptibility gene for schizophrenia. Biol. Psychiatry 55:192–195.PubMedGoogle Scholar
  147. Wolosker, H., Blackshaw, S., and Snyder, S. H. (1999). Serine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc. Natl. Acad. Sci. U. S. A. 96:13409–13414PubMedGoogle Scholar
  148. Woo, T. U., Walsh, J. P., and Benes, F. M. (2004). Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry. 61(7):649–657.Google Scholar
  149. Woo, T. U., Whitehead, R. E., Melchitzky, D. S., and Lewis, D. A. (1998). A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 95:5341–5346.PubMedGoogle Scholar
  150. Wroblewska, B., Wroblewski, J. T., Pshenichkin, S., Surin, A., Sullivan, S. E., and Neale, J. H. (1997). N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 69:174–181.PubMedCrossRefGoogle Scholar
  151. Xi, Z. X., Baker, D. A., Shen, H., Carson, D. S., and Kalivas, P. W. (2002). Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J. Pharmacol. Exp. Ther. 300:162–171.PubMedGoogle Scholar
  152. Yamasue, H., Iwanami, A., Hirayasu, Y., Yamada, H., Abe, O., Kuroki, N., et al. (2004). Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiatry Res. 131:195–207.PubMedGoogle Scholar
  153. Yurgelun-Todd, D. A., Coyle, J. T., Gruber, S. A., Renshaw, P. F., Silveri, M. M., Amico, E., Cohen, B., and Goff, D. C. (2005). Functional magnetic resonance imaging studies of schizophrenic patients during word production: Effects of D-cycloserine. Psychiatry Res. 138:23–31.PubMedGoogle Scholar
  154. Zafra, F., Gomeza, J., Olivares, L., Aragon, C., and Gimenez, C. (1995). Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur. J. Neurosci. 7:1342–1352.PubMedGoogle Scholar
  155. Zimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S., and Green, A. I. (2000). Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. J. Clin. Psychopharmacol. 20:94–98.PubMedGoogle Scholar
  156. Zornberg, G. L., Buka, S. L., and Tsuang, M. T. (2000). Hypoxic-ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study. Am. J. Psychiatry 157:196–202.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Harvard Medical SchoolMcLean HospitalBelmontUSA
  2. 2.Harvard Medical SchoolMcLean HospitalBelmontUSA

Personalised recommendations